简介：Objective:Toevaluatethesafetyandefficacyofexternalhigh-intensityfocusedultrasound(HIFU)castrationforbreastcancerouspatientsaftermastectomyiftheyareatahighriskofrecurrence.Methods:Werecruited52consecutivepatientswithprimaryoperablebreastcancerwhoweretreatedwithmastectomywithexcisionofregionallymphnodes.PatientswerepositiveforERandPRimmuno-cytochemicalstaining,node-positive,un-menopause,over40yearsoldandweredividedintotwogroupsrandomly.Forcastration,26patientsreceivedoneortwotimesofHIFUtreatmentwithinfivedays,andtheotherpatientsreceivedradiotherapywithDT18Gy/9f/11days.Duringandafterthetreatment,localchangesandsystemicresponseofthepatientswereobserved.Results:After1monthtreatment,levelsofserumE1andE2weresignificantlydecreasedcomparedtobeforetreatmentinHIFUgroups(P<0.01andP<0.001).Thesamechangeswereoccurredinradiotherapy(RT)groups(P<0.05andP<0.01).ThelevelsofserumE1orE2inRTgroupswerehigherthaninHIFUgroups(P<0.05).Thesymptomdistributionof'climactericsyndrome'ofHIFUgroupsweresignificantlydifferentfromRTgroups(P<0.01).Thefollow-uptimewas4months.Theincidenceofamenorrheawas100%inallpatients.Noseriouscomplicationswereseen.Thetemperature,pulse,bloodpressure,andrespiratoryrateofthepatientswerealmostnormal.Conclusion:WehaveshownthattheuseofHIFUinthecastratingofpatientswithbreastcancerisfeasible,safeandeffective.ThistechnologymayprovidearapidnoninvasivealterativetoconventionalbilateraloophorectomyorRTcastration.

简介：Allogeneicstemcelltransplantation(allo-SCT)isapotentialcureforpatientswithmalignantlymphomathatisbasedonthegraft-versus-lymphoma(GVL)effect.Myeloablativeconditioningallo-SCTisassociatedwithhighmortalityandmorbidity,particularlyinpatientsolderthan45years,heavilypretreatedpatients(priorhematopoieticstemcelltransplantationormorethantwolinesofconventionalchemotherapy)orpatientsaffectedbyothercomorbidities.Therefore,conventionalallo-SCTisrestrictedtoyoungerpatients(<50to55years)ingoodphysicalcondition.Overthelastdecade,allo-SCTwithreduced-intensityconditioning(RIC-allo-SCT)hasbeenincreasinglyusedtotreatpatientswithlymphoma.Thistreatmentisassociatedwithlowertoxicityandsubstantialdecreaseintheincidenceoftransplant-relatedmortality,andhasthepotentialtoleadtolong-termremissions.Therefore,patientswhoarenotsuitabletoundergoconventionalallo-SCTcanbenefitfromthepotentiallycurativeGVLeffectsofallo-SCT.AlthoughRIC-allo-SCThasimprovedthesurvivaloflymphomapatients,highpost-transplantrelapseratesordiseaseprogressionmainlyresultsintreatmentfailure.Thus,furtherimprovementisclearlyneeded.TheroleandtimingofRIC-allo-SCTinthetreatmentoflymphomaremainsunclear.Therefore,moreprospectivestudiesshouldclarifytheeffectivenessofthismethod.Inthisarticle,wereviewtherecentliteratureonRIC-allo-SCTasatreatmentformajorlymphomasubtypes.Areasthatrequirefurtherinvestigationinthecontextofclinicaltrialsarealsohighlighted.

简介：Bevacizumabisoneoftheraredrugsthatcouldimprovehigh-gradegliomaoutcomeafterfailureofchemoradiotherapy.However,todate,thereisnobiomarkerpredictiveforefficacyofbevacizumabtherapyintermsofsurvivalimprovementforpatientswithhigh-